metformin has been researched along with Arteriosclerosis in 41 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A low-dose combination of flutamide-metformin and ethinylestradiol-drospirenone was recently found to reduce the excess of total and abdominal fat, to diminish the deficit in lean mass, and to attenuate the dysadipocytokinemia of young women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 9.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. ( Cabré, S; De Zegher, F; Ibáñez, L; Valls, C, 2004) |
| "Flutamide (Flu)-metformin (Met) with ethinylestradiol-drospirenone is a combination therapy that reduces the total and abdominal fat excess, diminishes the lean mass deficit, and attenuates the dysadipocytokinemia of young and nonobese women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 9.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. ( de Zegher, F; Ibáñez, L, 2005) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 8.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| "A 69-year-old diabetic woman with diffuse atherosclerosis presented with acute renal failure due to contrast nephropathy and severe metformin-induced lactic acidosis." | 7.69 | Metformin-induced lactic acidosis associated with acute renal failure. ( Ben-Yehuda, A; Dranitzki-Elhalel, M; Popovtzer, M; Safadi, R, 1996) |
| " Chronic administration of BAPN did not produce plasma lipid abnormalities such as those due to hyperlipidic diet." | 5.26 | Chronic lathyrism and atheromatosis in the rat. Protective effect of metformin. ( Bouissou, H; Douste-Blazy, L; Julian, M; Pieraggi, MT; Thiers, JC, 1980) |
| "A low-dose combination of flutamide-metformin and ethinylestradiol-drospirenone was recently found to reduce the excess of total and abdominal fat, to diminish the deficit in lean mass, and to attenuate the dysadipocytokinemia of young women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 5.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. ( Cabré, S; De Zegher, F; Ibáñez, L; Valls, C, 2004) |
| "Flutamide (Flu)-metformin (Met) with ethinylestradiol-drospirenone is a combination therapy that reduces the total and abdominal fat excess, diminishes the lean mass deficit, and attenuates the dysadipocytokinemia of young and nonobese women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 5.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. ( de Zegher, F; Ibáñez, L, 2005) |
| "A 12-week double-blind placebo-controlled trial to study the effects of metformin on lipoprotein concentration and composition was performed in forty patients with NIDDM and hyperlipoproteinemia." | 5.07 | Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus. ( Schneider, J, 1991) |
| " Metformin is a biguanide compound which is antihyperglycaemic, reduces insulin resistance and has cardioprotective effects on lipids, thrombosis and blood flow." | 4.82 | Beneficial effects of metformin on haemostasis and vascular function in man. ( Grant, PJ, 2003) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 4.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| " Metformin and troglitazone, approved for use in the treatment of type 2 diabetes mellitus (DM), improve insulin sensitivity and lower plasma glucose concentrations." | 4.80 | Insulin resistance syndrome: options for treatment. ( Fonseca, VA; Granberry, MC, 1999) |
| "A 69-year-old diabetic woman with diffuse atherosclerosis presented with acute renal failure due to contrast nephropathy and severe metformin-induced lactic acidosis." | 3.69 | Metformin-induced lactic acidosis associated with acute renal failure. ( Ben-Yehuda, A; Dranitzki-Elhalel, M; Popovtzer, M; Safadi, R, 1996) |
| "Metformin is a widely used classic antidiabetic drug." | 2.80 | Metformin ameliorates the proinflammatory state in patients with carotid artery atherosclerosis through sirtuin 1 induction. ( Deng, YY; Gao, S; Liu, J; Maharjan, P; Tian, Y; Wang, L; Wu, Y; Xu, W; Yang, L; Yuan, Z; Zhao, S; Zhao, Y; Zhao, Z; Zhou, J; Zhuo, X, 2015) |
| "Troglitazone treatment of type 2 diabetic patients diminishes sCD40L levels, suggesting a novel antiinflammatory mechanism for limiting diabetes-associated arterial disease." | 2.71 | Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. ( Bernal, MR; Calle-Pascual, AL; Fernández-Cruz, A; Goldfine, A; Horton, E; Jarolim, P; Libby, P; Nuzzo, R; Schönbeck, U; Varo, JJ; Varo, N; Veves, A; Vicent, D, 2003) |
| "Insulin resistance is now considered to be major pathogenesis for diabetic macroangiopathy." | 2.43 | [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin]. ( Daita, H; Mokuno, H; Tamura, H, 2006) |
| "Metformin is a hypoglycaemic agent widely used in the management of type 2 diabetes." | 2.42 | Antiatherogenic properties of metformin: the experimental evidence. ( Mamputu, JC; Renier, G; Wiernsperger, NF, 2003) |
| "Insulin resistance is central to the pathogenesis of type 2 diabetes and may contribute to atherogenesis, either directly or through associated risk factors." | 2.42 | Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. ( Evans, M; Rees, A; Roberts, AW; Thomas, A, 2003) |
| " Finally, no dose-response relationship between cumulative exposure to metformin (dose x duration of treatment) and the serum total homocysteine level could be demonstrated." | 1.30 | Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? ( Bouter, LM; Heine, RJ; Hoogeveen, EK; Jakobs, C; Kostense, PJ; Stehouwer, CD, 1997) |
| " Chronic administration of BAPN did not produce plasma lipid abnormalities such as those due to hyperlipidic diet." | 1.26 | Chronic lathyrism and atheromatosis in the rat. Protective effect of metformin. ( Bouissou, H; Douste-Blazy, L; Julian, M; Pieraggi, MT; Thiers, JC, 1980) |
| "Metformin was selected as the test compound, because it has been shown to decrease aortic and liver lipid accumulation in cholesterol fed rabbits, while only slightly affecting plasma cholesterol levels." | 1.26 | Turnover and aortic uptake of very low density lipoproteins (VLDL) from hypercholesteremic rabbits as a model for testing antiatherosclerotic compounds. ( Catapano, A; Ghiselli, GC; Rodriguez, J; Sirtori, CR, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (36.59) | 18.7374 |
| 1990's | 8 (19.51) | 18.2507 |
| 2000's | 17 (41.46) | 29.6817 |
| 2010's | 1 (2.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, W | 1 |
| Deng, YY | 1 |
| Yang, L | 1 |
| Zhao, S | 1 |
| Liu, J | 1 |
| Zhao, Z | 1 |
| Wang, L | 1 |
| Maharjan, P | 1 |
| Gao, S | 1 |
| Tian, Y | 1 |
| Zhuo, X | 1 |
| Zhao, Y | 1 |
| Zhou, J | 1 |
| Yuan, Z | 1 |
| Wu, Y | 1 |
| Hemmingsen, B | 1 |
| Lund, SS | 1 |
| Vaag, A | 1 |
| Kaku, K | 1 |
| Iida, KT | 1 |
| Kawakami, Y | 1 |
| Suzuki, M | 1 |
| Shimano, H | 1 |
| Toyoshima, H | 1 |
| Sone, H | 1 |
| Shimada, K | 1 |
| Iwama, Y | 1 |
| Watanabe, Y | 1 |
| Mokuno, H | 2 |
| Kamata, K | 1 |
| Yamada, N | 1 |
| Varo, N | 1 |
| Vicent, D | 1 |
| Libby, P | 1 |
| Nuzzo, R | 1 |
| Calle-Pascual, AL | 1 |
| Bernal, MR | 1 |
| Fernández-Cruz, A | 1 |
| Veves, A | 1 |
| Jarolim, P | 1 |
| Varo, JJ | 1 |
| Goldfine, A | 1 |
| Horton, E | 1 |
| Schönbeck, U | 1 |
| Goodarzi, MO | 1 |
| Korenman, SG | 1 |
| Vague, P | 1 |
| Grant, PJ | 1 |
| Després, JP | 1 |
| Mamputu, JC | 1 |
| Wiernsperger, NF | 1 |
| Renier, G | 1 |
| Roberts, AW | 1 |
| Thomas, A | 1 |
| Rees, A | 1 |
| Evans, M | 1 |
| Matsumoto, K | 1 |
| Sera, Y | 1 |
| Abe, Y | 1 |
| Tominaga, T | 1 |
| Yeki, Y | 1 |
| Miyake, S | 1 |
| Ibáñez, L | 2 |
| Valls, C | 1 |
| Cabré, S | 1 |
| De Zegher, F | 2 |
| Miranda, PJ | 1 |
| DeFronzo, RA | 1 |
| Califf, RM | 1 |
| Guyton, JR | 1 |
| Ishida, W | 1 |
| Satoh, J | 1 |
| Tamura, H | 1 |
| Daita, H | 1 |
| Joffroy-Lavieuville, M | 1 |
| Triadou, N | 1 |
| Noel, M | 1 |
| Marquié, G | 5 |
| Baraldi, B | 1 |
| Maestri, G | 1 |
| Cusimano, A | 1 |
| Valenti, C | 1 |
| Tiraboschi, L | 1 |
| Cocuzza, E | 1 |
| Angeli, G | 1 |
| Sirtori, CR | 3 |
| Tremoli, E | 1 |
| Paoletti, R | 2 |
| Giacchi, M | 1 |
| Vatti, R | 1 |
| Bouissou, H | 1 |
| Thiers, JC | 1 |
| Douste-Blazy, L | 1 |
| Pieraggi, MT | 1 |
| Julian, M | 1 |
| Franceschini, G | 1 |
| Minchoff, LE | 1 |
| Grandin, JA | 1 |
| Safadi, R | 1 |
| Dranitzki-Elhalel, M | 1 |
| Popovtzer, M | 1 |
| Ben-Yehuda, A | 1 |
| Hoogeveen, EK | 1 |
| Kostense, PJ | 1 |
| Jakobs, C | 1 |
| Bouter, LM | 1 |
| Heine, RJ | 1 |
| Stehouwer, CD | 1 |
| Granberry, MC | 1 |
| Fonseca, VA | 1 |
| Taskinen, MR | 1 |
| Rodriguez, J | 1 |
| Catapano, A | 1 |
| Ghiselli, GC | 2 |
| Weber, G | 1 |
| Losi, M | 1 |
| Shore, B | 1 |
| Shore, V | 1 |
| Schneider, J | 1 |
| Fontbonne, A | 1 |
| André, P | 1 |
| Eschwège, E | 1 |
| Lafontan, M | 1 |
| Agid, R | 3 |
| Gormsen, J | 2 |
| Laursen, B | 2 |
| Molino, N | 1 |
| Belluardo, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients[NCT05951309] | 30 participants (Actual) | Interventional | 2021-09-01 | Completed | |||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for metformin and Arteriosclerosis
| Article | Year |
|---|---|
[Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Co | 2009 |
[Progress in therapy for diabetes mellitus--insulin-resistance ameliorating agents].
Topics: Animals; Arteriosclerosis; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus, Typ | 2009 |
The importance of insulin resistance in polycystic ovary syndrome.
Topics: Arteriosclerosis; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metfor | 2003 |
Is metformin more than an oral hypoglycaemic agent?
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; H | 2003 |
Beneficial effects of metformin on haemostasis and vascular function in man.
Topics: Arteriosclerosis; Blood Coagulation; Blood Platelets; Blood Vessels; Cardiovascular Diseases; Diabet | 2003 |
Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Arteriosclerosis; Blood Glucose; Body Constitution; Cardiovascular Diseases | 2003 |
Antiatherogenic properties of metformin: the experimental evidence.
Topics: Animals; Aortic Diseases; Arteries; Arteriosclerosis; Diabetes Mellitus, Type 2; Disease Models, Ani | 2003 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Resten | 2003 |
[Characteristic of metformin for treatment of impaired glucose tolerance].
Topics: Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Glucose; Glucose Intolerance; Humans; Hypog | 2005 |
[Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
Topics: Adiponectin; Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabeti | 2006 |
[Metformin, lipids and atherosclerosis].
Topics: Adipose Tissue; Adrenal Glands; Animals; Aorta; Apolipoproteins A; Apolipoproteins B; Arterioscleros | 1984 |
New strategies in the development of anti-atherosclerotic drugs.
Topics: 4-Aminobenzoic Acid; Animals; Arteriosclerosis; Aspirin; Coronary Disease; Fatty Acids, Nonesterifie | 1980 |
Drugs controlling triglyceride metabolism.
Topics: Anticholesteremic Agents; Arteriosclerosis; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Metf | 1993 |
Syndrome X. Recognition and management of this metabolic disorder in primary care.
Topics: Arteriosclerosis; Diabetes Mellitus, Type 2; Humans; Hypertension; Metabolic Diseases; Metformin; Ob | 1996 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipid | 1999 |
Strategies for the management of diabetic dyslipidaemia.
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemia | 1999 |
6 trials available for metformin and Arteriosclerosis
| Article | Year |
|---|---|
Metformin ameliorates the proinflammatory state in patients with carotid artery atherosclerosis through sirtuin 1 induction.
Topics: Aged; Arteriosclerosis; Carotid Artery Diseases; Female; Humans; Inflammation; Male; Metformin; Midd | 2015 |
Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Topics: Acute Disease; Adult; Aged; Arteriosclerosis; Body Mass Index; CD40 Ligand; Chromans; Chronic Diseas | 2003 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
Topics: Adiponectin; Adolescent; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.
Topics: Adolescent; Adult; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol; Fema | 2005 |
Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus.
Topics: Aged; Apoproteins; Arteriosclerosis; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; | 1991 |
BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance.
Topics: Adult; Aged; Arteriosclerosis; Data Collection; Data Interpretation, Statistical; Diabetes Mellitus; | 1991 |
19 other studies available for metformin and Arteriosclerosis
| Article | Year |
|---|---|
[Islands cells are not activated quickly enough. Risk of obstruction of blood vessels].
Topics: Arteriosclerosis; Blood Glucose; Cyclohexanes; Diabetic Angiopathies; Drug Therapy, Combination; Hum | 2002 |
Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, LDL; Chromans; Diabetes Mell | 2003 |
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.
Topics: Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Chronic Disease; Diabetes Mellitus, Typ | 2004 |
Metabolic syndrome: evaluation of pathological and therapeutic outcomes.
Topics: Arteriosclerosis; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Complications; Endotheli | 2005 |
Metformin action on lipid metabolism in lesions of experimental aortic atherosclerosis of rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Aortic Diseases; Arteriosclerosis; Cholesterol; Depression | 1983 |
[The anti-atherosclerotic effect of metformin in the initial phases of diabetes mellitus in adults].
Topics: Adult; Arteriosclerosis; Diabetes Mellitus; Diabetic Angiopathies; Drug Evaluation; Female; Humans; | 1980 |
[Inhibitory effect of metformin on the development of cholesterol atherosclerosis in the rabbit. Observations on the coronary vessels].
Topics: Animals; Arteriosclerosis; Cholesterol; Coronary Vessels; Diet, Atherogenic; Hypercholesterolemia; M | 1981 |
Chronic lathyrism and atheromatosis in the rat. Protective effect of metformin.
Topics: Aminopropionitrile; Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Diet, Atherogenic; Lath | 1980 |
Metformin-induced lactic acidosis associated with acute renal failure.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Arteriosclerosis; Blood Urea Nitrogen; Contrast Media; | 1996 |
Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus?
Topics: Adult; Aged; Arteriosclerosis; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Homocyste | 1997 |
Turnover and aortic uptake of very low density lipoproteins (VLDL) from hypercholesteremic rabbits as a model for testing antiatherosclerotic compounds.
Topics: Animals; Aorta; Apoproteins; Arteriosclerosis; Cholesterol; Disease Models, Animal; Hypercholesterol | 1976 |
Comparative effects of metformin and phenformin on the progression and regression of cholesterol induced athreosclerosis in rabbits.
Topics: Animals; Arteriosclerosis; Cholesterol, Dietary; Fatty Liver; Lipid Metabolism; Liver; Male; Metform | 1979 |
[Study of metformin in experimental arteriosclerosis (plasma lipoproteins, platelets, arteries and the pancreas)].
Topics: Animals; Arteries; Arteriosclerosis; Blood Platelets; Lipoproteins; Metformin; Pancreas; Rabbits | 1977 |
[Decrease of the incorporation of cholesterol-C 14 in the aorta after administration of dimethylbiguanide in normal rabbits].
Topics: Animals; Aorta; Arteriosclerosis; Carbon Radioisotopes; Cholesterol; Metformin; Rabbits | 1974 |
[Prevention with dimethylbiguanide of thyroid changes caused by an atherogenic diet in rabbits].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Diet, Atherogenic; Hypercholesterolemia; Hypoth | 1972 |
The effects of metformin on lipid-induced atherosclerosis.
Topics: Animals; Arteries; Arteriosclerosis; Blood Glucose; Cholesterol; Diet, Atherogenic; Fatty Acids, Non | 1973 |
Studies on pharmacological enhancement of blood fibrinolytic activity.
Topics: Aged; Arteriosclerosis; Clofibrate; Female; Fibrinogen; Fibrinolysis; Fibrinolytic Agents; Humans; I | 1970 |
Pharmacological enhancement and short-term stimulation of blood fibrinolytic activity.
Topics: Adolescent; Adult; Aged; Aminocaproates; Anticholesteremic Agents; Arteriosclerosis; Arthritis, Rheu | 1969 |
[Comparative study of the fibrinolytic activity of dimethylbiguanide in prevention of thromboembolism in patients with angiocardiopathy].
Topics: Adult; Aged; Arteriosclerosis; Coronary Disease; Dyspnea, Paroxysmal; Female; Humans; Hypertension; | 1968 |